Daiichi Sankyo’s revenue for Q3 FY2024 surged by 16.6% year-on-year, reaching 1,367.6 billion yen. This growth was primarily fueled by the company’s oncology division and its expansion into international markets. The core operating profit also saw a significant increase of 33%, amounting to 229 billion yen. CFO Koji Ogawa emphasized the company’s strong performance in oncology, with ENHERTU sales projected to hit 539.9 billion yen in FY2024. These figures underscore Daiichi Sankyo’s robust financial health and its strategic focus on oncology, which continues to drive its market momentum.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
